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An Inflammatory Role for the Mammalian
Carboxypeptidase Inhibitor Latexin: Relationship
to Cystatins and the Tumor Suppressor TIG1
Anna Aagaard,1 Pawel Listwan,2,3 the lateral neocortex (hence latexin) of the developing
mammalian brain (Arimatsu, 1994). It has been used toNathan Cowieson,1 Thomas Huber,4
Timothy Ravasi,1,3,5 Christine A. Wells,1 elucidate the mechanism of cortical regional specifica-
tion, and it was suggested to play a role in the modula-Jack U. Flanagan,3 Stuart Kellie,1,2,3
David A. Hume,1,3,5 Bostjan Kobe,1,2,5 tion of sensory perception (Bai et al., 2004). It is thought
that latexin functions in inflammation and innate im-and Jennifer L. Martin1,2,5,*
1Institute for Molecular Bioscience mune pathways because it is expressed by rat mast
cells, it inhibits mast cell CPA3, and it localizes to a2School of Molecular and Microbial Sciences
3Cooperative Research Centre for Chronic novel population of mast cell granules, distinct from the
classical exocytic granule classes (Uratani et al., 2000).Inflammatory Diseases
4Department of Mathematics Furthermore, latexin is induced in acute pancreatitis
and lung inflammatory disease (Ji et al., 2003). Here,5ARC Special Research Centre for Functional
and Applied Genomics we present new evidence for a role for latexin in inflam-
mation by showing that its expression is induced inUniversity of Queensland
Brisbane, QLD 4072 stimulated mouse macrophages in concert with poten-
tial protease targets and other protease inhibitors.Australia
Although unrelated to known CPIs, latexin does
share sequence similarity with TIG1 (Figure 1, w30%
Summary identity over 220 residues), a protein found in mouse,
rat, and human. TIG1 is expressed in skin fibroblasts
Latexin, the only known mammalian carboxypepti- and epithelia, and it is encoded by a retinoic acid (RA)
dase inhibitor, has no detectable sequence similarity receptor-responsive gene. It has been implicated in
with plant and parasite inhibitors, but it is related to both the therapeutic effects of RA in psoriasis (Nagpal
a human putative tumor suppressor protein, TIG1. et al., 1996) and, more recently, in tumor suppression
Latexin is expressed in the developing brain, and we (Jing et al., 2002). TIG1 is larger than latexin, and the
find that it plays a role in inflammation, as it is ex- additional residues are thought to encode a membrane
pressed at high levels and is inducible in macro- anchor at the N terminus (Nagpal et al., 1996).
phages in concert with other protease inhibitors and Other proteins with sequence identity (w30%) to la-
potential protease targets. The crystal structure of texin are found in chicken (ovocalyxin [Hincke et al.,
mouse latexin, solved at 1.83 Å resolution, shows no 2003]) and Xenopus (Figure 1), but no related proteins
structural relationship with other carboxypeptidase were found in nonvertebrates. Chicken ovocalyxin is a
inhibitors. Furthermore, despite a lack of detectable protein involved in egg shell production. This similarity,
sequence duplication, the structure incorporates two the vertebrate-restricted gene family, and the reported
topologically analogous domains related by pseudo expression of latexin in osteoblasts (Balint et al., 2003)
two-fold symmetry. Surprisingly, these domains share suggest roles for latexin in bone regulation and calcifi-
a cystatin fold architecture found in proteins that inhibit cation.
cysteine proteases, suggesting an evolutionary and To gain insight into the function of latexin, we investi-
possibly functional relationship. The structure of the gated its expression profile in macrophages, deter-
tumor suppressor protein TIG1 was modeled, reveal- mined its crystal structure, and used the structure to
ing its putative membrane binding surface. model that of TIG1. The latexin structure reveals unex-
pected pseudosymmetry and a previously unknown re-
Introduction lationship with the cysteine protease inhibitor cystatin.
Latexin, or tissue carboxypeptidase inhibitor (TCI), is Results
the only known mammalian carboxypeptidase inhibitor
(CPI), and recombinant rat latexin has been shown to Latexin Is Macrophage Enriched and Inducible
inhibit pancreatic carboxypeptidase A1 (CPA1), CPA2 In light of a possible role for latexin in inflammation, we
(Ki w3 nM), and CPA3 (mast cell carboxypeptidase, Ki examined expression in macrophages, the major cell
16 nM) (Normant et al., 1995). Comprising over 220 resi- type recruited to acute and chronic inflammatory sites.
dues, the protein is significantly larger than CPIs from We have previously reported extensive analyses of
plants and parasites (40–70 residues). Furthermore, la- gene expression profiles in mouse macrophages from
texin lacks the conserved 7-residue C terminus of these several mouse strains (Wells et al., 2003a). These analy-
shorter CPIs that interacts with CPA in a substrate-like ses indicate that the gene encoding latexin forms part
manner (Reverter et al., 2000). The loss of the C termi- of a set that is highly enriched in macrophages com-
nus suggests that latexin and the plant/parasite CPIs pared to other cell types and tissues, and is highly ex-
have distinctly different mechanisms of CPA inhibition. pressed in macrophage-rich tissues such as spleen and
Latexin was first identified as a marker of neurons in liver (Wells et al., 2003b). The latexin gene also fell
within a cluster of genes induced in macrophages by
the major lineage-specific growth factor, colony stimu-*Correspondence: j.martin@imb.uq.edu.au
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Figure 1. Sequence Alignments
(A) Multiple sequence alignment of mouse, rat, and human latexin (m_latexin, NP_058033.2; r_latexin, NP_113843.1; h_latexin, AAF82807.1);
human, rat, and mouse TIG1 (h_TIG1, AAH29640.1; r_TIG1, XP_227232.2; m_TIG1, XP_130987.2); Xenopus laevis latexin-like protein (Xp_
unknown, AAH59975.1); and chicken ovocalyxin (CAC44378.2). The number of N- or C-terminal residues not shown in the alignment are
indicated in parentheses. Residue numbers and secondary structure for mouse latexin are shown. Residues conserved throughout are shaded
in dark gray, and where the residue is conserved in all but one, it is shaded in light gray.
(B) Structure-based sequence alignment of the N- and C-terminal latexin domains (Lxn1 and Lxn2, respectively), chicken cystatin (cCYS, PDB
accession code 1CEW [Bode et al., 1988]), human Stefin B (hSTFB, 1STF [Stubbs et al., 1990]), and monellin (MONB and MONA, respectively,
for the two peptides, 1MOL [Somoza et al., 1993]). Residues that can be structurally aligned with the N-terminal domain of latexin are
highlighted in light gray. Residues that are identical—after structural alignment—with the N-terminal domain of latexin are highlighted in dark
gray, and residues from human Stefin B that interact with the cysteine protease papain (1STF [Stubbs et al., 1990]) are shaded in black.
lating factor 1 (CSF-1), in combination with the patho- ases or protease inhibitors. By comparison, TIG1 gene
expression is also high in macrophages but does notgen product, lipopolysaccharide (LPS).
To confirm the latexin expression profile identified by change upon stimulation.
using cDNA microarrays, we performed real-time PCR
analysis in LPS-stimulated bone marrow-derived macro- Structure of Latexin
Based upon its expression profile in macrophages, la-phages in the presence or absence of CSF-1. Latexin
mRNA was, indeed, expressed at high levels in macro- texin and its target CPA represent potential targets for
therapeutic intervention in chronic inflammatory disease.phages, and it was further induced by a combination of
LPS and CSF-1 (Figure 2). Other genes induced by LPS As no latexin homologs with known structures could be
identified, we determined its structure by X-ray crystal-in murine macrophages included CPA3 (mast cell CP),
a known interaction partner of latexin, carboxypepti- lography by using MAD methods and SeMet-labeled
protein. The structure has one molecule in the asym-dase D (this has been noted previously, Hadkar and
Skidgel, 2001), and the cysteine protease inhibitors metric unit and was refined at 1.83 Å resolution (Table 1).
Although there is no evidence of internal symmetrycystatin C and cystatin F (Figure 2). Indeed, w8% of
genes upregulated under this stimulation encode prote- from the polypeptide sequence, the crystal structure re-
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neously giving an rmsd of 2.1 Å for the Cα atoms of 142
aligned residues (Figure 3).
The major structural differences between the two do-
mains are variations in β strand lengths and different
loop conformations and sizes. This is particularly strik-
ing for the loop connecting the first β strand and the α
helix of each domain (β1-α1 and β6-α3, respectively).
In domain 2, this loop comprises 11 residues (residues
121–131) that protrude from the core, while the equiva-
lent loop in domain 1 is formed from five residues (resi-
dues 4–8) (Figure 1B).
Latexin Comprises Two Cystatin-like Folds
No other protein was found to have the same overall
topology as latexin (DALI [Holm and Sander, 1993]);
however, the individual domains share the topology of
the cystatin/monellin family of proteins (Figure 4) (Mur-
zin et al., 1995). Cystatins are cysteine protease inhibi-
tors, and monellin is a sweet-tasting protein from the
West African berry Dioscoreophyllum cumminsii (So-
Figure 2. Expression in Macrophages moza et al., 1993). The cystatin/monellin fold is charac-
(A) Quantitative real-time PCR profiles of latexin mRNA showing terized by a five-stranded antiparallel β sheet and a
dynamic expression after LPS stimulation in macrophages over central α helix. The structure of chicken cystatin (Bode
time, in concert with other protease inhibitors and potential target
et al., 1988) is the most similar to latexin (rmsd of 1.6 Åproteases. The expression peak for latexin is at 7 hr, when the mac-
and 14 [17%] identical residues for the comparison ofrophage response to LPS also reaches a maximum.
84 Cα atoms with the latexin N-terminal domain).(B) Quantitative real-time PCR profiles of latexin mRNA showing
the effect of the growth factor CSF-1. The plotted data have been Although there is no overall sequence relationship
normalized as described in the Experimental Procedures. between latexin and cystatins (Figure 1B), the structural
relationship suggests an evolutionary and possibly a
functional relationship. When submitted as individual
domains, the meta-server 3D-JURY (Ginalski et al.,veals two structurally related domains (domains 1 and
2) linked by a connecting helix (α2) (Figure 3). Each do- 2003) predicted the sequence of domain 1, but not do-
main 2, to have a cystatin-like structure. Furthermore,main comprises a five-stranded antiparallel β sheet
wrapped around an α helix. The sequence identity be- in the genes encoding both human and mouse latexin,
the position between domains 1 and 2 corresponds totween the two domains is w11% after structural align-
ment (Figure 1B), yet the Cα atoms of 84 residues of an intron-exon boundary, with each domain encoded
by three exons (data not shown). These data suggestdomains 1 and 2 overlay with an rmsd of 1.9 Å. Extra-
ordinarily, the pseudosymmetry is such that both do- that latexin may have evolved from an ancestral cys-
tatin-like protein as a consequence of a gene duplica-mains can be superimposed on the other, simulta-
Table 1. Data Collection and Refinement Statistics
Data Collection
MAD (SeMet) Native
Wavelength (Å) 0.9794 0.9796 0.9077 1.0781
Resolution range (Å) 50–1.96 50–1.96 50–1.96 50–1.83 (1.9–1.83)a
Observed reflections 413,797 392,101 399,913 426,598
Unique reflections 22,703 22,622 22,591 29,633
Rmergeb 0.073 0.071 0.060 0.039 (0.422)a
Completeness (%) 99.9 99.9 99.1 99.7 (100)a
<I>/<σ(I)> 18.5 15.3 12.8 19.9 (4.5)a
Refinement
Resolution of data used in refinement 50.0–1.83 (1.94–1.83)a
Number of reflections total/test set 28,971/2,897
Rfacc and Rfreed (%) 21.1 (25.9)a and 23.7 (26.8)a
Number of protein atoms/waters 1,871/184
Rmsd from ideal geometry: bonds (Å)/angles (°) 0.011/1.5
Ramachandran: most favored/disallowed regions (%) 91.3/0.0
a Parentheses refer to the highest resolution shell.
b Rmerge = S|I − <I>|/S<I>; I is the intensity of each reflection.
c Rfac = Sh|Fo − Fc|/Sh|Fo|; Fo and Fc are observed and calculated structure-factor amplitudes for each reflection, h.
d Rfree for 10% of data selected randomly and excluded from refinement.
Structure
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Figure 3. Crystal Structure
(A) Stereo diagram of the electron density
(2Fo-Fc contoured at 2σ) around the cis-pro-
line region (Ile122-cisPro123-Asp-124).
(B) Schematic of the latexin structure show-
ing β strands as arrrows and α helices as
spirals. The N-terminal subdomain (residues
1–97) is red, the C-terminal subdomain (resi-
dues 118–222) is orange, and the linking α
helix is green.
(C) Superposition of the two subdomains,
residues 1–97 (red) on residues 118–222
(green) and residues 118–222 (red) on resi-
dues 1–97 (green). Some loops were re-
moved for clarity.
(D) Surface renderings of latexin showing
(left) a putative binding surface predicted
from PROMATE (Neuvirth et al., 2004); the
best-predicted binding surface is shown in
blue, the less probable binding surface is
shown in white, and the least probable bind-
ing surface is shown in red. The surface on
the right shows the conservation of residues
across the three mammalian latexins, ovo-
calyxin, and Xenopus latexin-like protein
(which together make one branch in the phy-
logenetic tree, with the TIG1 proteins form-
ing another branch). The color scheme is
green for highly conserved residues, white
for less conserved proteins, and yellow for
least conserved proteins.
The figure was generated by using GRASP
(Nicholls et al., 1993), MOLSCRIPT (Kraulis,
1991), and Raster3D (Merritt and Murphy,
1994) or by using BOBSCRIPT (Esnouf, 1999)
and Povray (www.povray.org).
tion event. The overall gene structure for cystatins is are conserved in these inhibitors, but not in latexin;
therefore, a common mechanism of inhibition can besimilar to that for the individual domains of latexin in
that there are three exons and two introns. However, ruled out (Normant et al., 1995). Previous sequence
analysis studies identified a limited degree of similaritythe length and sequence of the introns and exons are
not conserved between cystatins and latexin domains, between an 11-residue sequence of latexin (200-LWHPQ
YGTKVK-210) and the prosegment of carboxypepti-suggesting that if the latexin N-terminal domain evolved
from an ancestral cystatin, the divergence would have dase B (CPB) (37-FWKPDSATQVK-47) (Normant et al.,
occurred early in evolution. The presence of two cys- 1995). It was therefore suggested that this region of la-
tatin-like domains also suggests the possibility that texin may inhibit CPs by mimicking the prosegment of
cleavage may be required for activity. However, there is the enzymes. However, the two sequence motifs form
no evidence of cleavage of recombinant mouse latexin; very different secondary structures in their respective
it forms a stable complex with bovine CPA (data not proteins, indicating that this mechanism of inhibition
shown). is unlikely.
We used structural approaches to identify potential
binding sites on latexin. The program ProMate (Neu-Carboxypeptidase Binding
virth et al., 2004) identified a surface patch that in-Crystal structures of the potato and leech CPIs in com-
cludes residues 174-FI-175, 204-PQ-205, and T208plex with CPA2 revealed that the C-terminal tail of the
(Figure 3D). This region from the C-terminal domain ofinhibitors interacts with the active site of CPA in a sub-
latexin includes the residues that are similar in se-strate-like manner (Rees and Lipscomb, 1982; Reverter
et al., 2000). The C-terminal residues (-Pro-Tyr-Val-X) quence to the proCPB region described above, and it
Cellular and Structural Studies on Latexin
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Figure 4. Diversity and Similarity in CP Inhibi-
tors, Cystatin, and Monellin
(A–F) Structures of CP inhibitors from (A) po-
tato (4CPA [Rees and Lipscomb, 1982]) and
(B) leech (1DTV [Reverter et al., 2000]) are
very different from the structure of mamma-
lian CP inhibitor, (C) latexin. However, latexin
(N-terminal domain, [D]) is structurally re-
lated to proteins in the (E) cystatin (cysteine
protease inhibitor, chicken cystatin) (1CEW
[Bode et al., 1988]) and (F) monellin (sweet-
tasting protein) (1MOL [Somoza et al., 1993])
fold family.
also includes a loop equivalent to one of the papain- proteins that are related overall by only 30% identity
suggests that the cis form of the peptide bond will alsointeracting regions of the cystatin human Stefin B
(170-RNDDFI-175 of latexin, corresponding to VAGT of be present in TIG1 and the Xenopus and ovocalyxin
proteins. Furthermore, the position of the cis-prolinehuman Stefin B, highlighted in Figure 1B). Some con-
served residues also map to this area of the surface motif on a protruding loop is suggestive of a protein
interaction surface.(Figure 3D), though this analysis is hampered by the
low number of latexin sequences available.
Structure of TIG1
Alignment of latexin and TIG1 sequences illustratesHeparin and Sulfate Binding
Latexin also interacts directly with a heparin compo- that differences exist between the two proteins as well
as within the TIG1 family. The most notable of these isnent in the mast cell population of granules (Uratani et
al., 2000). We identified the potential binding surface by the presence of a variable length N-terminal extension
in TIG1 relative to latexin (Figure 1) that is predicted tousing GRID (Goodford, 1985) with a sulfate anion probe.
At high-energy contour levels (−9.0 kcal/mol), a sulfate form a transmembrane helix.
Models of human latexin and human TIG1 were de-binding site was observed near Arg171. Analysis of the
electrostatic properties of the protein surface (GRASP rived by homology modeling based on the crystal struc-
ture of mouse latexin. The electrostatic surfaces of hu-[Nicholls et al., 1993]) supports the identification of this
basic patch as a sulfate binding site. Moreover, the man latexin and human TIG1 (Figure 5) show that the
two proteins have strikingly different charge distribu-close proximity of another basic patch, formed by resi-
dues Lys208, Lys210, and His211 on strand 9, could tions on one face, with TIG1 having a predominantly
basic surface. This surface may interact with mem-coordinate other sulphates on a heparin sulfate oligo-
mer. This hypothesis is supported by docking a mast branes, given that human TIG1 is predicted to be mem-
brane bound. The opposite face of TIG1 has featurescell granule heparin sulfate pentasaccharide onto the
mouse latexin surface. Of 50 solutions, 43 had a sulfate common to latexin. A basic patch is present in a similar
location to that created by Lys18 and Lys159 in mousegroup in the vicinity of the proposed sulfate binding
pocket identified by GRID, and 26 had another sulfate latexin and Lys159 in human latexin. The surface
around this patch is more hydrophobic in human TIG1positioned close to the basic patch.
compared to human latexin (due to substitutions of
Lys159 to Tyr, Ile62 to Tyr, Glu33 to Val, and Gln18 toConservation of a cis-Proline Motif
Leu), and the negative patch at the helix 2 end of theThe structure of latexin incorporates a cis-peptide
cleft is reduced in size. Furthermore, the residues defin-bond between residues Ile122 and Pro123. These resi-
ing the heparin binding site identified in the mouse la-dues are located in a protruding loop between the first
texin structure, and also present in the human and ratβ strand (β6) and α helix (α3) of domain 2. The density
latexin isoforms, are not conserved in TIG1.in this region is well defined (Figure 3), and the se-
quence in this region (IPDXXG) is conserved throughout
the latexin/TIG1 family of proteins (Figure 1). Indeed, Discussion
with four of six residues conserved in all eight proteins,
this is the most highly conserved motif in the entire se- Latexin is the only known mammalian carboxypepti-
dase inhibitor. We have found that latexin is expressedquence. This high degree of conservation in a family of
Structure
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mediate secretion. In this respect, latexin could resem-
ble the serpin plasminogen activator inhibitor type 2
(PAI-2), which is a cytoplasmic protein located and reg-
ulated quite differently from its target, plasminogen ac-
tivator (Costelloe et al., 1999). However, in mast cells,
latexin has a granular localization and associates with
a subpopulation of vesicles (Uratani et al., 2000), and
we have confirmed that latexin is also expressed in a
discrete granule population in macrophages (A. Bur-
rows, D.A.H., and S.K., unpublished data).
Latexin is thought to be a noncompetitive inhibitor of
CPA (Normant et al., 1995). This mode of inhibition
makes it difficult to predict putative interaction sites,
because the binding site may not necessarily involve
the enzyme active site. Analysis of the latexin structure
reveals a number of features that could represent pro-
tein interaction sites, without the need to invoke con-
formational changes. The electrostatic surface of la-
texin reveals a basic patch formed by residues from the
α helices of both subdomains (Lys18 and Lys159). The
two subdomains are arranged so that there is a cleft in
this part of the structure that could accommodate a
peptide chain. Another intriguing feature is the protrud-
ing nature of the loop incorporating a cis-peptide and
comprising residues 121–131. Clearly, it is there for aFigure 5. Comparison of Human Latexin and Human TIG1
purpose, since the cis-proline region is highly con-(A–D) Electrostatic surfaces are shown for (A and B) human latexin
and (C and D) TIG1 based on models derived from the crystal struc- served throughout the wider latexin/TIG1 family. This
ture of mouse latexin. The broadly basic surface of (C) TIG1—absent conservation is indicative of a conserved structure and
in (A) latexin—suggests an interaction surface for phospholipid possibly a conserved function. Conversely, there is only
membranes, consistent with a predicted membrane anchor at the one region in the protein sequences (Figure 1) that isN terminus of TIG1. (B and D) A basic patch on the opposite face
hypervariable—the loop between β3 and β4. This loopof both proteins is indicated. This is also present, and more promi-
varies in length (6–14 residues) and sequence (Figure 1)nent, in mouse latexin (not shown). The figure was produced by
using GRASP (Nicholls et al., 1993). over all eight proteins, yet it is highly conserved within
latexin or TIG1 subfamilies. The loop therefore repre-
sents a point of unusual variability in a seemingly well-constitutively at high basal levels in mouse macro-
conserved protein scaffold and will be of considerable
phages and can be further upregulated by stimulation
interest should TIG1 proteins subsequently be shown
of the cells with a growth factor or proinflammatory
not to have CPI activity.
stimulus. Upregulation occurs in parallel with several
The disparate sizes and sequences of latexin and the
other types of protease inhibitors and target proteases. plant/parasite CPIs indicated a piori that they would
The known targets of latexin are the three isoforms of encode very different protein folds, and this is borne
CPA, though it is possible that latexin may interact with out by the structural comparison (Figure 4). What was
and regulate the activity of other proteases. entirely unexpected was the striking similarity between
Nevertheless, the available data strongly suggest a the subdomains of latexin and proteins of the cystatin/
role for CPA and latexin in inflammation, and other CPs, monellin superfamily (Figure 4). This similarity suggests
including CPM, have been shown to correlate with the possiblity that latexin may have cysteine protease
macrophage cytotoxic activity (Rehli et al., 2000). CPA inhibitor activity. However, the residues in cystatins that
has been reported to be involved in the production or are involved in binding are conserved within the cys-
regulation of several proinflammatory mediators. In vi- tatin family, but are not present in latexin. Indeed, the
tro, CPA from mast cells degrades endothelin-1, raising sequence similarity between latexin and the cystatins
the possibility that it limits endothelin-mediated vaso- is very low.
constriction and proliferation (Metsarinne et al., 2002). The sequence similarity between latexin and TIG1
Pancreatic CPA has also been shown to convert the suggests that the latter may have protease inhibitor ac-
potent leukotriene C4 to the less potent leukotriene F4 tivity, though this is not yet tested to our knowledge.
by hydrolysis of an amide bond, again suggesting a Similarly, there is no evidence that latexin plays a tumor
negative role in inflammation (Reddanna et al., 2003). suppressor role, though its partner protein CPA3 has
However, purified bovine CPA can induce NFκB-depen- been shown to be induced in prostate cancer cells (Hu-
dent TNFα production from macrophages, suggesting a ang et al., 1999). However, if sequence identity between
proinflammatory role (Jaffray et al., 2000). The balance latexin and the C-terminal domain of TIG1 translates to
between CPA and latexin could thus lead to either en- structural and functional similarity, it is possible that
hancement or inhibition of inflammation, depending on TIG1 tumor suppressor function could be a conse-
other mediators present. quence of extracellular proteolysis inhibition. This has
One puzzling aspect is that latexin contains no signal parallels elsewhere in tumor biology; for example, the
serine protease inhibitor maspin is a tumor suppressorpeptide or predicted hydrophobic segments that could
Cellular and Structural Studies on Latexin
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as an energy source, thereby preventing expression of genes con-because it inhibits cell motility, invasion, and angiogen-
trolled by the lac-operon. After incubation at 37°C for a day, theesis (Sager et al., 1997).
culture was inoculated (1/100) into a rich medium containing glu-In summary, we have shown that proteolysis in gene-
cose and lactose and then incubated overnight at 37°C. Typically,
ral, and latexin in particular, play a role in the immune OD600 was 5–6 at harvest, and the yield of latexin was 100 mg/l
response, since the latexin gene is highly expressed in culture. The His-tagged protein was purified by metal affinity chro-
matography (Talon, Clontech). After elution, the buffer was ex-macrophages and its expression is further regulated by
changed with 10 mM Hepes (pH 7.5), 150 mM NaCl, 10% glycerol,several proinflammatory stimuli. We solved the crystal
1 mM DTT, and the protein was concentrated to w50 mg/ml.structure of latexin, and this unexpectedly revealed a
Selenomethionine (SeMet)-labeled latexin was produced as de-relationship between the carboxypeptidase inhibitor la-
scribed previously for other proteins (Edeling et al., 2002) and puri-
texin and the cysteine protease inhibitors, cystatins. fied in the same way as native protein. Incorporation of SeMet was
We identified a cis-proline loop in latexin that is likely verified by mass spectrometry by using a PE SCIEX API III triple-
quadrupole mass spectrometer.to be important for function and that is conserved in
the tumor suppressor protein TIG1.
Crystal Structure
Crystals were obtained by hanging-drop vapor diffusion after 5–7Experimental Procedures
days by mixing 1 l protein solution with 1 l reservoir containing
1.8 M ammonium sulfate, 0.1 M cacodylate (pH 6.5) (space groupDifferentiation of Bone Marrow-Derived Macrophages
P43212 and unit cell dimensions a = b = 104.14 Å, c = 60.04 Å).Bone marrow-derived macrophages were obtained from femurs of
Crystals of SeMet latexin were grown in the same way and ap-a pool of 6- to 8-week-old male mice. Macrophages were differenti-
peared after 3–4 days. Crystals were flash-cooled after soaking forated from bone marrow progenitors in RPMI1640 (BRL), 10% fetal
10 s in a cryoprotectant containing 25% glycerol, 2.0 M ammoniumcalf serum, and 104 U/ml (100 ng/ml) recombinant CSF-1 (a gift
sulfate, and 0.1 M cacodylate (pH 6.5). X-ray diffraction data (MADfrom Chiron, Emeryville, CA) for 6 days. Macrophages were seeded
and native) were measured at beamline 8.2.2 of the Advanced Lightat 1 × 107 cells/ml and incubated with 10 ng/ml LPS from Salmo-
Source (ALS) at Lawrence Berkeley National Laboratory (LBNL,nella minnesota (Sigma-Aldrich, St. Louis, MO). 3 × 10 cm dishes
Berkeley, CA) and were processed and scaled by using HKL2000were harvested at each time point—unstimulated (time 0), 30 min,
(Otwinowski and Minor, 1997).2 hr, 7 hr, and 21 hr. RNA was extracted by using the RNeasy midi
SOLVE (Terwilliger, 2003) was used to locate six seleniums andkit (Qiagen) according to manufacturer’s instructions. Replica data
to provide initial phases for refinement (mean figure of merit = 0.7).were derived from independent RNA extractions of a different pool
Automatic model building was performed with ARP/WARP (Morrisof 6- to 8-week-old mouse femurs.
et al., 2003) within the CCP4 package (CCP4, 1994). The resulting
model consisting of 179 amino acids was used as a starting pointQuantitative Real-Time PCR
for model building in O (Jones et al., 1991) and refinement by maxi-Total RNA (2.5 g) of each sample was treated with DNase 1 (Am-
mum likelihood and individual B factor refinement against nativebion, Austin, TX) and reverse-transcribed by using 17mer oligo-dT
data at 1.83 Å resolution with CNS (Brunger et al., 1998).and the Superscript III RnaseH− reverse transcriptase kit, or the
The final model includes residues 1–217 of latexin and 3 residuesSuperscript III First-Strand Synthesis system for RT-PCR (Invitro-
from the 28-residue tag (denoted −2, −1, and 0). The five C-terminalgen). Negative control samples (no first strand synthesis) were pre-
residues (218–222) were not included due to poor electron density.pared by performing reactions in the absence of reverse tran-
scriptase. The reaction after reverse transcription (20 l) was
Modeling and Analysisdiluted to 100 l with water. Five l diluted cDNA was used for
Alignments between the proteins were generated by CLUSTALXquantitative real-time PCR performed by using the LightCycler-
(Jeanmougin et al., 1998) with default parameters. Models for theDNA Master SYBR Green I kit (Roche). The PCR was performed by
C-terminal region of rat, mouse, and human TIG1 corresponding tousing an ABI Prism machine (Applied Biosystems): 1 min hot start
the latexin sequence were constructed by using MODELLER (Saliat 94°C, followed by 45 cycles of 1 s at 94°C, 10 s at 60°C, and 15
and Blundell, 1993) with mouse latexin structure as the template.s at 72°C. cDNA levels during the linear phase of amplification were
The highest refinement level in HOMOLOGY (INSIGHTII, Accelrys)normalized against hypoxanthine phosphoribosyltransferase con-
was used. The modeling procedure was iterative; in each iteration,trols. Assays were done in triplicate, and mean ± SD was deter-
10 models were constructed and compared. The lowest energymined. Primers used for the amplification of murine latexin: forward
structure was used for further refinement. The stereochemical qual-5#-TTCGAAGGAGAAATCGGCAA-3# and reverse 5#-GGGATGTCC
ity of models was checked by using PROCHECK (Laskowski et al.,TGTGCTTCCAG-3#.
1993), as implemented in the Biotech validation suite at 1.9 Å reso-
lution.Expression and Purification
Sulfate binding pockets were identified by using GRID (Good-A pool of cDNA species generated by using mRNA extracted from
ford, 1985) with a charged oxygen of a sulfate or phosphate usedmurine bone marrow-derived macrophages treated with LPS over
as a probe with grid spacing of 0.5 Å. Docking calculations werea time course of up to 24 hr (Wells et al., 2003a) was used as the
performed by using GOLD (v2.0) (Verdonk et al., 2003) for the bind-template for PCR amplification. Mouse latexin cDNA (669 nucleo-
ing of a pentasaccharide (1AZX [Jin et al., 1997]; energy minimizedtides) was amplified by using the forward primer 5#-CACCATG
in BUILDER [INSIGHTII] by using the esff force-field) representingGAAATCCCACCCACCCAC-3# and reverse primer 5#-TCACTCCG
mast cell granule heparin. Fifty dockings were performed in theCCTGCCCTTCC-3# (start codon for translation is shown in bold) by
binding site defined as a 20 Å sphere centered on Arg171, andusing Eppendorf Triple Master blunt-ended proof-reading polymer-
these were ranked according to the GoldScore fitness functionase. The 50 l PCR reaction contained 10 l enzyme buffer, 100 ng
(Verdonk et al., 2003). Cavity detection was not used; other param-of each primer, 1 l 20 mM dNTPs, 0.5 l cDNA, and 0.3 l enzyme.
eters were set to defaults.The cycling conditions included initial denaturation for 2 min at
95°C, followed by 30 cycles of denaturation at 95°C for
30 s, annealing at 55°C for 45 s, and elongation at 68°C for 1 min.
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